Clinical trial · Interventional
Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor
Effects of Exenatide on Body Weight in Patients With Hypothalamic Obesity
NCT01484873CI-TRIAL-00026259completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether exenatide can cause weight loss in patients with a history of craniopharyngioma or other brain lesion.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Craniopharyngioma | Craniopharyngioma | ONTOLOGY_EXACT | 0.90 |
| Obesity | — | UNRESOLVED | — |
| Overweight | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Exenatide | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Exenatide
- description
- All patients received exenatide 10mcg BID x 50 weeks
- interventionNames
- Drug: Exenatide
Primary outcomes (1)
- measure
- Body Weight (kg)
- timeFrame
- baseline, 50 weeks
- description
- Change in body weight from baseline to end of study
Secondary outcomes (4)
- measure
- Resting Energy Expenditure (Kcals Per Day)
- timeFrame
- baseline, 50 weeks
- description
- Change in resting energy expenditure from baseline to 50 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 to 40 years old * History of craniopharyngioma or other lesion in the hypothalamic region * Greater than 6 months post-treatment, including chemotherapy, surgery or radiation * BMI \>30 mg/m2 * Females must be post-menopausal, surgically sterile or using effective birth control for at least 12 weeks Exclusion Criteria: * HgbA1C \>7% * Use of diabetes medications other than metformin in the past 12 weeks, including exenatide * Use of weight loss drugs or initiation of a weight loss program in past 3 months * Impaired renal function or history of kidney transplant * History of gall stones (unless s/p cholecystectomy), pancreatitis or alcoholism * Personal or family history of medullary carcinoma of the thyroid or MEN type 2 * History of gastroparesis or other gastric motility problems as exenatide decreases gastric motility * History of allergic reaction to exenatide or other medication components * Other significant comorbidities other than pituitary deficiencies * Currently prescribed warfarin (exenatide may alter warfarin metabolism) * Pregnant or lactating females * History of severe hypoglycemia (BG \<60 and requiring assistance from another person)
References
Publications (1)
- RESULTLomenick JP, Buchowski MS, Shoemaker AH. A 52-week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity. Obesity (Silver Spring). 2016 Jun;24(6):1222-5. doi: 10.1002/oby.21493. Epub 2016 May 2. PMID 27133664